Influenza

Lancet

Volumn 362, Issue 9397, 2003, Pages 1733-1745

  Nicholson, Karl G ^a   Wood, John M ^b   Zambon, Maria ^c  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

^b NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^c CENTRAL PUBLIC HEALTH LABORATORY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; INACTIVATED VACCINE; INFLUENZA VACCINE; SIALIDASE; SIALIDASE INHIBITOR;

CONFERENCE PAPER; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; MEDICAL DECISION MAKING; MEDICAL RESEARCH; MOLECULAR RECOGNITION; PATHOGENICITY; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION; SEVERE ACUTE RESPIRATORY SYNDROME;

EID: 0344983434     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)14854-4     Document Type: Conference Paper

References (140)

1. Turner D, Wailoo A, Nicholson K, Cooper N, Sutton A, Abrams K. Systematic review and economic decision modeling for the prevention and treatment of influenza A and B. http://www.nice.org.uk/pdf/influenzaassrep.pdf (accessed Oct 15, 2003).
2. Nicholson K.G., Webster R.G., Hay A.J. Textbook of influenza. 1998;Blackwell Science, Oxford.
3. Simonsen L., Clarke M.J., Williamson G.D., Stroup D.F., Arden N.H., Schonberger L.B. The impact of influenza epidemics on mortality: introducing a severity index. Am J Public Health. 87:1997;1944-1950.
4. Wright P.F., Thompson J., Karzon D.T. Differing virulence of H1N1 and H3N2 influenza strains. Am J Epidemiol. 112:1980;814-819.
5. Frank A.L., Taber L.H., Wells J.M. Comparison of infection rates and severity of illness for influenza A subtypes H1N1 and H3N2. J Infect Dis. 151:1985;73-80.
6. Monto A.S., Koopman J.S., Longini I.M. The Tecumseh study of illness: XIII, influenza infection and disease, 1976-1981. Am J Epidemiol. 121:1985;811-822.
7. Simonsen L., Fukuda K., Schonberger L.B., Cox N.J. The impact of influenza epidemics on hospitalizations. J Infect Dis. 181:2000;831-837.
8. Nicholson K.G. Impact of influenza and respiratory syncytial virus on mortality in England and Wales from January 1975 to December 1990. Epidemiol Infect. 116:1996;51-63.
9. Thompson W.W., Shay D.K., Weintraub E., et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 289:2003;179-186.
10. Meier C.R., Napalkov P.N., Wegmüller Y., Jefferson T., Jick H. Population-based study on incidence, risk factors, clinical complications and drug utilization associated with influenza in the United Kingdom. Eur J Clin Microbiol Infect Dis. 19:2000;834-842.
11. Glezen W.P., Decker M., Perrotta D.M. Survey of underlying conditions of persons hospitalized with acute respiratory disease during influenza epidemics in Houston, 1978-1981. Am Rev Respir Dis. 136:1987;550-555.
12. Neuzil K.M., Wright P.F., Mitchel E.F., Griffin M.R. Burden of influenza illness in children with asthma and other chronic medical conditions. J Pediatr. 137:2000;856-864.
13. Izurieta H.S., Thompson W.W., Kramarz P., et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med. 342:2000;232-239.
14. Neuzil K.M., Mellen B.G., Wright P.F., Mitchel E.F., Griffin M.R. Effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med. 342:2000;225-231.
15. Chiu S.S., Lau Y.L., Chan K.H., Wong W.H.S., Peiris J.S.K. Influenza-related hospitalisations among children in Hong Kong. N Engl J Med. 347:2002;2097-2103.
16. Outbreak of influenza, Madagascar, July-August 2002. Wkly Epidemiol Rec 2002; 46: 381-84.
17. Cox N.J., Brammer T.L., Regnery H.L. Influenza: global surveillance for epidemic and pandemic variants. Eur J Epidemiol. 10:1994;467-470.
18. Cox N.J., Regnery H.L. Global influenza surveillance: tracking a moving target in a rapidly changing world. In: Brown LE, Hampson AW, Webster RG, eds. Options for the control of influenza III. Amsterdam: Elsevier. International Congress Series. 1123:1996;591-598.
19. Claas E.C.J., Osterhaus A.D.M.E., Van Beek R., et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet. 351:1998;472-477.
20. Yuen K.Y., Chan P.K.S., Peiris M., et al. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet. 351:1998;467-471.
21. Chen W., Ni H., Huang P., Zhou H., Liu S. Surveillance of influenza viruses in Guandong Province, China in 1998: a preliminary report. Osterhaus A.D.M.E., Cox N., Hampson A.W. Options for the control of influenza IV. 2001;123-129 Excerpta Medica, Amsterdam. International Congress Series 1219.
22. Peiris M., Yuen K.Y., Leung C.W., et al. Human infection with influenza H9N2. Lancet. 354:1999;916-917.
23. Uyeki T.M., Chong Y.H., Katz J.M., et al. Lack of evidence for human-to-human transmission of avian influenza A H9N2 viruses in Hong Kong, China, 1999. Emerging Infect Dis. 8:2002;154-160.
24. Guan Y., Shortridge K.F., Krauss S., Webster R.G. Molecular characterization of H9N2 influenza viruses: were they the donors of the "internal" genes of H5N1 viruses in Hong Kong? Proc Natl Acad Sci USA. 96:1999;9363-9367.
25. Gregory V., Bennett M., Orkhan M.H., et al. Emergence of influenza A H1N2 reassortant viruses during 2001. Virology. 300:2002;1-9.
26. Ellis J., Zambon M.C. Molecular diagnosis of influenza. Rev Med Virol. 12:2002;375-389.
27. Guo Y., Xu X., Cox N.J. Human influenza A (H1N2) viruses isolated from China. J Gen Virol. 73:1992;383-388.
28. Li X.S., Zhao C.Y., Gao H.M., et al. Origin and evolutionary characteristics of an antigenic reassortant virus isolated from man in China. J Gen Virol. 73:1992;1329-1337.
29. Webster R.G., Geraci J., Petursson G., Skirnisson K. Conjunctivitis in human beings caused by influenza A virus of seals. N Engl J Med. 304:1981;911.
30. Kurtz J., Manvell R.J., Banks J. Avian influenza virus isolated from a woman with conjunctivitis. Lancet. 348:1996;901-902.
31. Fouchier R. Avian influenza, human-Netherlands (09): fatal case. Reported in: ProMED-mail [online]. Boston: International Society for Infectious Diseases, report no 20030419.0959, April 19, 2003 ( http://www.promedmail.org ).
32. Ryan-Poirier K.A., Katz J.M., Webster R.G., Kawaoka Y. Application of Directigen FLU-A for the detection of influenza A virus in human and nonhuman specimens. J Clin Microbiol. 30:1992;1072-1075.
33. Dominguez E.A., Taber L.H., Couch R.B. Comparison of rapid diagnostic techniques for respiratory syncytial and influenza A virus respiratory infections in young children. J Clin Microbiol. 31:1993;2286-2290.
34. Kaiser L., Briones M.S., Hayden F.G. Performance of virus isolation and Directigen Flu A to detect influenza A virus in experimental human infection. J Clin Virol. 14:1999;191-197.
35. Noyola D.E., Demmler G.J. Effect of rapid diagnosis on management of influenza A infections. Pediatr Infect Dis J. 19:2000;303-307.
36. Chan K.H., Maldeis N., Pope W., et al. Evaluation of Directigen Flu A and B for rapid diagnosis of influenza type A and B infections. J Clin Microbiol. 40:2002;1675-1680.
37. Reina J., Padilla E., Alonso F., Ruiz De Gopegui E., Munar M., Mari M. Evaluation of a new dot blot enzyme immunoassay (Directigen Flu A+B) for simultaneous and differential detection of influenza a and B virus antigens from respiratory samples. J Clin Microbiol. 40:2002;3515-3517.
38. Rodriguez W.J., Schwartz R.H., Thorne M.M. Evalaution of diagnostic tests for influenza in a pediatric practice. Pediatr Infect Dis J. 21:2002;193-196.
39. Noyola D.E., Paredes A.J., Clark B., Demmler G.J. Evaluation of a neuraminidase detection assay for the rapid detection of influenza A and B virus in children. Pediatr Dev Pathol. 3:2000;162-167.
40. Poehling K.A., Griffin M.R., Dittus R.S., et al. Bedside diagnosis of influenzavirus infections in hospitalized children. Pediatrics. 110:2002;83-88.
41. Quach C., Newby D., Daoust G., Rubin E., McDonald J. QuickVue influenza test for rapid detection of influenza A and B viruses in a pediatric population. Clin Diagn Lab Immunol. 9:2002;925-926.
42. Effler P.V., Ieong M.C., Tom T., Nakata M. Enhancing public health surveillance for influenza virus by incorporating newly available rapid diagnostic tests. Emerg Infect Dis. 8:2002;23-28.
43. Monto A.S., Gravenstein S., Elliott M., Colopy M., Schweinle J. Clinical signs and symptoms predicting influenza infection. Arch Intern Med. 160:2000;3243-3247.
44. Gravenstein S, Schilling M, Drinka P, et al. Influenza B presentation in vaccinated elderly patients: diagnostic considerations. Options for the control of influenza IV, Hersonnissos, Crete, Greece, Sept 23-28, 2000: 140, abstr P2-54.
45. Monto A.S., Ohmit S.E., Margulies J.R., Talsma A.N. Medical practice-based influenza surveillance: viral prevalence and assessment of morbidity. Am J Epidemiol. 141:1995;502-506.
46. Heijnen M.L.A., Dorigo-Zetsma J.W., Bartelds A.I.M., Wilbrink B., Sprenger M.J.W. Surveillance of respiratory pathogens and influenza-like illnesses in general practices-The Netherlands, winter 1997/98. Eurosurveillance. 4:1999;81-84.
47. Zambon M.C., Stockton J.D., Clewley J.P., Fleming D.M. Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational study. Lancet. 358:2001;1410-1416.
48. Zambon M.C. Pathogenesis of influenza A and B in humans. Rev Med Virol. 11:2001;227-241.
49. Chen J., Lee K.H., Steinhauer D.A., Stevens D.J., Skehel J.J., Wiley D.C. Structure of the hemagglutinin precursor cleavage site, a determinant of influenza pathogenicity and the origin of the labile conformation. Cell. 95:1998;409-417.
50. Steinhauer D.A. Role of hemagglutinin cleavage for the pathogenicity of influenza virus. Virology. 258:1999;1-20.
51. Perdue ML, Suarez DL. Structural features of the avian influenza virus haemagglutinin that influence virulence. Vet Microbiol 2000; 77-86. (A: please give volume number).
52. Taubenberger J.K., Reid A.H., Krafft A.E., Bijwaard K.E., Fanning T.G. Initial genetic characterization of the 1918 "Spanish" influenza virus. Science. 275:1997;1793-1796.
53. Reid A.H., Fanning T.G., Hultin J.V., Taubenberger J.K. Origin and evolution of the 1918 "Spanish" influenza virus hemagglutinin gene. Proc Natl Acad Sci USA. 96:1999;1651-1656.
54. Hatta M., Gao P., Halfmann P., Kawaoka Y. Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses. Science. 293:2001;1840-1842.
55. Seo S.H., Hoffmann E., Webster R.G. Lethal H5N1 influenza viruses escape host anti-viral cytokine responses. Nat Med. 8:2002;950-954.
56. Cheung C.Y., Poon L.L.M., Lau A.S., et al. Induction of pro-inflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet. 360:2002;1831-1837.
57. Garcia Sastre A., Egerov A., Matassov D., et al. Influenza A virus lacking the NS1 gene replicates in interferon deficient systems. Virology. 252:1998;324-330.
58. Morishima T., Togashi T., Yokota S., et al. Encephalitis and encephalopathy associated with an influenza epidemic in Japan. Clin Infect Dis. 35:2002;512-517.
59. Sugaya N. Influenza-associated encephalopathy in Japan. Semin Pediatr Infect Dis. 13:2002;79-84.
60. Nicholson K.G., Nguyen-Van-Tam J.S., Ahmed A.H., et al. Randomised placebo-controlled crossover trial on effect of inactivated influenza vaccine on pulmonary function in asthma. Lancet. 351:1998;326-331.
61. Sener M., Gursel G., Turktas H. Effects of inactivated influenza virus vaccination on bronchial reactivity symptom scores and peak expiratory flow variability in patients with asthma. J Asthma. 36:1999;165-169.
62. Castro M., Dozor A., Fish J., et al. The safety of inactivated influenza vaccine in adults and children with asthma. N Engl J Med. 345:2001;1529-1536.
63. Lasky T., Terracciano G.J., Magder L., et al. The Guillain-Barré syndrome and the 1993 and 1993-1994 influenza vaccines. N Engl J Med. 339:1998;1797-1802.
64. Gruber W.C., Taber L.H., Glezen P., et al. Live attenuated and inactivated influenza vaccine in school-age children. Am J Dis Child. 144:1990;595-600.
65. Clover R.D., Crawford S., Glezen W.P., Taber L.H., Matson C.C., Couch R.B. Comparison of heterotypic protection against influenza A/Taiwan/86 (H1N1) by attenuated and inactivated vaccines to A/Chile/83-like viruses. J Infect Dis. 163:1991;300-304.
66. Neuzil K.M., Dupont W.D., Wright P.F., Edwards K.M. Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience. Pediatr Infect Dis J. 20:2001;733-740.
67. Khan A.S., Polezhaev F., Vasiljeva R., et al. Comparison of US inactivated split virus and Russian live attenuated, cold-adapted trivalent influenza vaccines in Russian schoolchildren. J Infect Dis. 173:1996;453-456.
68. Hurwitz E.S., Haber M., Chang A., et al. Studies of the 1996-1997 inactivated influenza vaccine among children attending day care: Immunologic response, protection against infection, and clinical effectiveness. J Infect Dis. 182:2000;1218-1221.
69. Edwards K.M., Dupont W.D., Westrich M.K., Plummer W.D., Palmer P.S., Wright P.F. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis. 169:1994;68-76.
70. Wilde J.A., McMillan J.A., Serwint J., Butta J., O'Riordan M.A., Steinhoff M.C. Effectiveness of influenza vaccine in health care professionals. JAMA. 281:1999;908-913.
71. Govaert T.M.E., Thijs C.T.M.C.N., Masurel N., Sprenger M.J.W., Dinant G.J., Knottnerus J.A. The efficacy of influenza vaccination in elderly individuals: a randomized double-blind placebo-controlled trial. JAMA. 272:1994;1661-1665.
72. Deguchi Y., Takasugi Y., Tatara K. Efficacy of influenza vaccine in the elderly in welfare nursing homes: reduction in risks of mortality and morbidity during an influenza A (H3N2) epidemic. J Med Microbiol. 49:2000;553-556.
73. Boulianne N., De Serres G., Duval B., Shadmani R., Rochette L. Clinical manifestations and incidence of oculo-respiratory syndrome following influenza vaccination-Quebec 2000. Can Commun Dis Rep. 27:2001;85-90.
74. Choudhri Y., Walop W., Squires S., et al. ORS during the 2000-2001 influenza vaccination season. Can Commun Dis Rep. 28:2002;2-8.
75. Rudenko L.G., Slepuskin A.N., Monto A.S., et al. Efficacy of attenuated and inactivated influenza vaccines in school children and their unvaccinated contacts in Novgorod, Russia. J Infect Dis. 168:1993;881-887.
76. Heikkinen T., Ruuskanen O., Waris M., Ziegler T., Arola M., Halonen P. Influenza vaccination in the prevention of acute otitis media in children. Am J Dis Child. 145:1991;445-448.
77. Clements D.A., Langdon L., Bland C., Walter E. Influenza A vaccine decreases the incidence of otitis media in 6 to 30-month-old children in day care. Arch Pediatr Adolesc Med. 149:1995;1113-1117.
78. Kramarz P., Destefano F., Gargiullo P.M., et al. Does influenza vaccination prevent asthma exacerbations in children? J Pediatr. 138:2001;306-310.
79. Hurwitz E.S., Haber M., Chang A., et al. Effectiveness of influenza vaccination of day care children in reducing influenza-related morbidity among household contacts. JAMA. 284:2000;1677-1682.
80. Nichol K.L., Lind A., Margolis K.L., et al. The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med. 333:1995;889-893.
81. Saxen H., Virtanen M. Randomized, placebo-controlled double blind study on the efficacy of influenza immunization on absenteeism of health care workers. Pediatr Infect Dis J. 18:1999;779-783.
82. Bridges C.B., Thompson W.W., Meltzer M.I., et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA. 284:2000;1655-1663.
83. Nicholson K.G., Kent J., Hammersley V. Influenza A among community-dwelling elderly persons in Leicestershire during winter 1993-4; cigarette smoking as a risk factor and efficacy of influenza vaccination. Epidemiol Infect. 123:1999;103-108.
84. Mullooly J.P., Bennett M.D., Hornbrook M.C., et al. Influenza vaccination programs for elderly persons: cost effectiveness in a health maintenance organization. Ann Intern Med. 121:1994;947-952.
85. Nichol K.L., Wuorenma J., von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern Med. 158:1998;1769-1776.
86. Nordin J., Mullooly J., Poblete S., et al. Influenza vaccine effectiveness in preventing hospitalizations and deaths in persons 65 years or older in Minnesota, New York, and Oregon: data from 3 health plans. J Infect Dis. 184:2001;665-670.
87. Fedson D.S., Wajda A., Nicol J.P., Hammond G.W., Kaiser D.L., Roos L.L. Clinical effectiveness of influenza vaccination in Manitoba. JAMA. 270:1993;1956-1961.
88. Ahmed A.H., Nicholson K.G., Nguyen-Van-Tam J.S., Pearson J.C.G. Effectiveness of influenza vaccine in reducing hospital admissions during the 1989-90 epidemic. Epidemiol Infect. 18:1997;27-33.
89. Foster D.A., Talsma A., Furumoto-Dawson A., et al. Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly. Am J Epidemiol. 136:1992;296-307.
90. Ohmit S.E., Monto A.S. Influenza vaccine effectiveness in preventing hospitalization among the elderly during influenza type A and type B seasons. Int J Epidemiol. 24:1995;1240-1248.
91. Puig-Barbera J., Marquez-Calderon S., Masoliver-Fores A., et al. Reduction in hospital admission for pneumonia in non-institutionalised elderly people as a result of influenza vaccination: a case-control study in Spain. J Epidemiol Community Health. 51:1997;526-530.
92. Crocetti E., Arniani S., Bordoni F., Maciocco G., Zappa M., Buiatti E. Effectiveness of influenza vaccination in the elderly in a community in Italy. Eur J Epidemiol. 17:2001;163-168.
93. Davis J.W., Lee E., Taira D.A., Chug R.S. Influenza vaccination, hospitalisations, and costs among members of a Medicare managed care plan. Med Care. 39:2001;1273-1280.
94. Fleming D.M., Watson J.M., Nicholas S., Smith G.E., Swan A.V. Study of the effectiveness of influenza vaccination in the elderly in the epidemic of 1989-90 using a general practice database. Epidemiol Infect. 115:1995;581-589.
95. Vu T., Farish S., Jenkins M., Kelly H. A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine. 20:2002;1831-1836.
96. Gross P.A., Hermogenes A.W., Sacks H.S., Lau J., Levandoski R.A. The efficacy of influenza vaccine in elderly persons: a meta-analysis and review of the literature. Ann Intern Med. 123:1995;518-527.
97. Nichol K.L., Baken L., Nelson A. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. Ann Intern Med. 130:1999;397-403.
98. Hak E., von Essen C.A., Buskens E., de Melker R.A. Is immunizing all patients with chronic lung disease in the community against influenza cost-effective? Evidence from a general practice based clinical prospective cohort study in Utrecht, the Netherlands. J Epidemiol Community Health. 52:1998;120-125.
99. Lavallee P., Perchaud V., Gautier-Bertrand M., Grabli D., Amarenco P. Association between influenza vaccination and reduced risk of brain infarction. Stroke. 33:2002;513-518.
100. Naghavi M., Barlas Z., Siadaty S., Naguib S., Madjib M., Casscells W. Association of influenza vaccination and reduced risk of recurrent myocardial infarction. Circulation. 102:2000;3039-3045.
101. Siscovick D.S., Raghunathan T.E., Lin D.Y., et al. Influenza vaccination and the risk of primary cardiac arrest. Am J Epidemiol. 152:2000;674-677.
102. Colquhoun A.J., Nicholson K.G., Botha J.L., Raymond N.T. Effectiveness of influenza vaccine in reducing hospital admissions in people with diabetes. Epidemiol Infect. 119:1997;335-341.
103. Potter J., Stott D.J., Roberts M.A., et al. Influenza vaccination of health care workers in long-term care hospitals reduces the mortality of elderly patients. J Infect Dis. 175:1997;1-6.
104. Carman W.F., Elder A.G., Wallace L.A., et al. Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled trial. Lancet. 355:2000;93-97.
105. Oshitani H., Saito R., Seki N., et al. Influenza vaccination levels and influenza-like illness in long-term-care facilities for elderly people in Niigata, Japan, during an influenza A (H3N2) epidemic. Infect Control Hosp Epidemiol. 21:2000;728-730.
106. Banzhoff A., Nacci P., Podda A. A new MF-59-adjuvanted influenza vaccine enhances the immune response in the eldeerly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology. 49:2003;177-184.
107. Holm K.J., Goa K.L. Liposomal influenza vaccine. Biodrugs. 11:1999;137-146.
108. Belshe R.B., Mendelman P.M., Treanor J., et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med. 338:1998;1405-1412.
109. Belshe R.B., Gruber W.C., Mendelman P.M., et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr. 136:2000;168-175.
110. Jefferson T.O., Demicheli V., Deeks J.J., Rivetti D. Amantadine and rimantadine for preventing and treating influenza A in adults (Cochrane Review). The Cochrane Library, Issue 4. 2001;Update Software, Oxford.
111. National Institute for Clinical Excellence. Guidance on the use of zanamivir, oseltamivir and amantadine for the treatment and prophylaxis of influenza. Technology appraisal guidance, no 58, February 2003. http://www.nice.org.uk/pdf/58_Flu_fullguidance.pdf (accessed Oct 15, 2003).
112. Freund B., Gravenstein S., Elliott M., Miller I. Zanamivir: a review of clinical safety. Drug Safety. 4:1999;267-281.
113. US Food and Drug Administration. Relenza. http://www.fda.gov/cder/news/ relenza/default.htm (accessed Oct 15, 2003).
114. Cass L.M., Gunawardena K.A., MacMahon M.M., Bye A. Pulmonary function and airway responsiveness in mild to moderate asthmatics given repeated inhaled doses of zanamivir. Respir Med. 94:2000;166-173.
115. Murphy K.R., Eivindson A., Pauksens K., et al. Efficacy and safety of inhaled zanamivir for the treatment of influenza in patients with asthma or chronic obstructive pulmonary disease: a double-blind, randomised, placebo-controlled, multicentre study. Clin Drug Invest. 20:2000;337-349.
116. Diggory P., Fernadez C., Jumphrey A., Jones V., Murphy M. Comparison of elderly people's technique in using two dry powder inhalers to deliver zanavivir: randomised controlled trial. BMJ. 322:2001;1-4.
117. Hayden F.G., Osterhaus A.D.M.E., Treanor J.J., et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. N Engl J Med. 337:1997;874-880.
118. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B infections. Lancet. 352:1998;1877-1881.
119. Mäkela M.J., Pauksens K., Rostila T., et al. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomised, double-blind, placebo-controlled European study. J Infect. 40:2000;42-48.
120. Hayden F.G., Gubareva L.V., Monto A.S., et al. Inhaled zanamivir for the prevention of influenza in families. N Engl J Med. 343:2000;1282-1289.
121. Murphy K.R., Eivindson A., Pauksens K., et al. Efficacy and safety of inhaled zanamivir for the treatment of influenza in patients with asthma or chronic obstructive pulmonary disease: a double-blind, randomised, placebo-controlled, multicentre study. Clin Drug Invest. 20:2000;337-349.
122. Hedrick J.A., Barzilai A., Behre U., et al. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr Infect Dis J. 19:2000;410-417.
123. Monto A.S., Webster A., Keene O. Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. J Antimicrob Chemother. 44:1999;23-29.
124. Lalezari J., Campion K., Keene O., Silagy C. Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials. Arch Intern Med. 161:2001;212-217.
125. Monto A.S., Robinson D.P., Herlocher M.L., Hinson J.M., Elliott M.J., Crisp A. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA. 282:1999;31-35.
126. Kaiser L., Henry D., Flack N.P., Keene O., Hayden F.G. Short-term treatment with zanamivir to prevent influenza: results of a placebo-controlled study. Clin Infect Dis. 30:2000;587-589.
127. Hayden F.G., Atmar R.L., Schilling M., et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med. 341:1999;1336-1343.
128. Welliver R., Monto A.S., Carewicz O., et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA. 285:2001;748-754.
129. Nicholson K.G., Aoki F.Y., Osterhaus A.D.M.E., et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised trial. Lancet. 355:2000;1845-1850.
130. Treanor J.J., Hayden F.G., Vrooman P.S., et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza. JAMA. 283:2000;1016-1024.
131. Whitley R.J., Hayden F.G., Reisinger K.S., et al. Oral oseltamivir in treatment of influenza in children. Pediatr Infect Dis J. 20:2001;127-133.
132. Peters P.H., Gravenstein S., Norwood P., et al. Long term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail elderly population. J Am Geritr Soc. 49:2001;1025-1031.
133. Gubareva L.V., Matrosovich M.N., Brenner M.K., Bethell R.C., Webster R.G. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis. 178:1998;1257-1262.
134. http://www.rocheusa.com/products/tamiflu/pi.html # MICROBIOLOGY (accessed Oct 15, 2003).
135. National Institute for Clinical Excellence. Guidance on the use of oseltamivir and amantadine for the prophylaxis of influenza. Technology appraisal guidance, no 67, September 2003. http://www.nice.org.uk/pdf/ 67_Flu_prophylaxis_guidance.pdf (accessed Oct 15, 2003).
136. Li S.Q., Liu C.G., Klimov A., et al. Recombinant influenza A virus vaccines for the pathogenic human A Hong Kong 97 (H5N1) viruses. J Infect Dis. 179:1999;1132-1138.
137. Treanor J.J., Wilkinson B.E., Masseoud F., et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine. 19:2001;1732-1737.
138. Nicholson K.G., Colegate A.E., Podda A., et al. Safety and antigenicity of non-adjuvanted and MF-59 adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomized trial of two potential vaccines against H5N1 influenza. Lancet. 357:2001;1937-1943.
139. Hehme N., Engelmann H., Kunzel W., Neumeier E., Sanger R. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines. Med Microbiol Immunol (Berl). 191:2002;203-208.
140. http://www.who.int/emc/diseases/flu/whoguidelines.htm (accessed Oct 15, 2003).